Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Rediscovering Euphoria: Individual Accounts of Conquering Despondency22.09.2023 - 2Carry Nature Inside with These Staggering Plant Decisions06.06.2024
- 3You finally got a doctor's appointment. Here's how to get the most out of it20.12.2025
- 4FBI arrests Brian Cole Jr. in Jan. 6 pipe bomb investigation, ending 5-year hunt04.12.2025
- 5Argentina reportedly delaying embassy move over Israeli company's oil project near Falklands11.01.2026
- EU waters down plans to end new petrol and diesel car sales by 2035
- Before trips to Mars, we need better protection from cosmic rays
- Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- Everyone knows F1 is for the girls. I wandered into the Las Vegas desert to find out why.
- First Alert: Light snow through this evening
- Language Learning Stages: Which One Gets Your Vote?
- AfD in Brandenburg takes back suit against the intelligence service
- Volcanic eruption led to the Black Death, new research suggests
- Best Veggie lover Dinner: What's Your Plant-Based Pick?
